Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Ciclesonide→

Ciclesonide Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
126544-47-6
Molecular formula
C32H44O7
Molecular weight
540.69 g/mol
Drug class
Inhaled/intranasal glucocorticoidcorticosteroid prodrug
Mechanism of action
Ciclesonide is converted by esterases in airway and nasal tissues to the active metabolite des-ciclesonide, which binds glucocorticoid receptors and suppresses inflammatory gene expression and mediator release.
Indications / reported uses
  • Maintenance treatment of asthma with inhaled formulations; not intended for relief of acute bronchospasm
  • Treatment or prevention of symptoms of seasonal and perennial allergic rhinitis with authorised intranasal formulations; age eligibility is product- and jurisdiction-specific

Sources: US DailyMed — Ciclesonide products · NLM MeSH — Ciclesonide · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Inhaled/intranasal glucocorticoid; corticosteroid prodrug

Mechanism of action

Ciclesonide is converted by esterases in airway and nasal tissues to the active metabolite des-ciclesonide, which binds glucocorticoid receptors and suppresses inflammatory gene expression and mediator release.

General use cases

  • Maintenance treatment of asthma with inhaled formulations; not intended for relief of acute bronchospasm
  • Treatment or prevention of symptoms of seasonal and perennial allergic rhinitis with authorised intranasal formulations; age eligibility is product- and jurisdiction-specific

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Ciclesonide Environmental Risk Assessment (ERA) (the Ciclesonide ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.